The first edition of ACTSS in 2017 was a huge success and the market approval of KYMRIAH® and YESCARTA® gave the industry a lot to discuss. Over the last 12 months, CAR-T has become an increasingly exciting field to work in and we have witnessed new technology, clinical development and regulatory advances globally. Billion dollar deals were closed on CAR-T assets and millions have been invested in start-ups focused on advanced therapy development.
This year we will explore developments in global regulations in cell and gene therapy, discuss critical insights into cGMP manufacturing best practices and explore next generation technologies and their potential to shape the autologous CAR-T landscape in the next 3-5 years.
Together we will take another step towards driving sustainable success in advanced therapies!